Request Demo

Last update 20 Aug 2026

Hydrochlorothiazide

Last update 20 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryHydrochlorothiazide, a small molecule drug, targets the NCC co-transporter as an inhibitor, exhibiting an assortment of therapeutic effects. The drug, first approved on February 12th, 1959, and originally developed by Novartis, is primarily used to treat edema, hypertension, and kidney calculi, and may be used to manage diabetes insipidus. Hydrochlorothiazide operates by obstructing the reabsorption of sodium and chloride ions in the distal convoluted tubule of the kidney, producing augmented excretion of water and electrolytes. This, in turn, reduces edema and lowers blood pressure. However, while the drug can be beneficial, it can also be associated with a range of side effects, including electrolyte imbalances and low blood pressure, and should be used with caution in patients with severe kidney disease. It is of utmost importance to only use Hydrochlorothiazide under the guidance of a healthcare provider, and patients should be carefully monitored for any adverse effects. In summary, Hydrochlorothiazide presents a diverse array of benefits for managing numerous conditions, yet the appropriateness of its use should be carefully tailored to each individual patient.

Drug Type

Small molecule drug

Synonyms

HCTZ, Hydrochlorothiazide (JP17/USP/INN), 氢氯噻嗪微片

+ [11]

Target

NCC

Action

inhibitors

Mechanism

NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

Nephrotic SyndromeDiabetes InsipidusEdema+ [2]

Inactive Indication

Diabetes Mellitus, Type 2Essential Hypertension

Originator Organization

Novartis Pharma AG

Active Organization

Tianjin Lisheng Pharmaceutical Co., Ltd.

Beijing CoSci Med-Tech Co., Ltd.

Novitium Pharma LLC

+ [4]

Inactive Organization

Novartis AG

Boehringer Ingelheim GmbH

Novartis Pharmaceuticals Canada, Inc.

+ [1]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 Feb 1959),

Hypertension

Regulation-

Structure/Sequence

Molecular FormulaC7H8ClN3O4S2

InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N

CAS Registry58-93-5

317

Clinical Trials associated with Hydrochlorothiazide

NCT07593612

/ Not yet recruitingPhase 4

TACTIC-HF: Thiazide or Acetazolamide Combination Versus Intravenous Furosemide in Ambulatory Worsening Heart Failure - a Randomized Crossover Trial

TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program.
Participants will receive sequential treatment with:
1. intravenous furosemide alone,
2. intravenous furosemide combined with oral acetazolamide, and
3. intravenous furosemide combined with oral hydrochlorothiazide.
The primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal/electrolyte safety.
Each participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit.
The study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.

Start Date15 Jun 2026

Sponsor / Collaborator

Instituto Cardiovascular De Buenos Aires SA

NCT07634068

/ Not yet recruitingPhase 2IIT

Vertebrobasilar Dolichoectasia Treatment With Amiloride: a Pilot Study Based On 5.0 T MRI

The aim of this pilot study is to assess the efficacy of amiloride in reducing wall enhancement in vertebrobasilar dolichoectasia(VBD) on high-resolution magnetic resonance vessel wall imaging(HR-VWI) via anti-inflammatory mechanisms, clarify the efficacy of amiloride in delaying the progression of VBD, evaluate the safety of amiloride in the treatment of VBD.

Start Date01 Jun 2026

Sponsor / Collaborator

Shanghai Huashan Hospital

NCT07469722

/ Not yet recruitingPhase 2/3IIT

Point-of-care Ultrasound Intervention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure

Acute decompensated heart failure (ADHF) is a frequent cause of hospitalization and is associated with high morbidity and mortality. Congestion is the primary pathophysiological mechanism leading to clinical deterioration and hospitalization in ADHF. Diuretics remain the cornerstone of treatment for most ADHF phenotypes; however, evidence regarding optimal strategies to guide diuretic therapy during the decongestion process is limited. Recently, point-of-care ultrasound (POCUS) has emerged as a promising tool to support clinical assessment in ADHF, improving diagnostic accuracy, prognostication, and pre-discharge evaluation. Nevertheless, the role of POCUS in guiding therapeutic management in ADHF remains uncertain. To specifically assess congestion in patients with ADHF, a pragmatic POCUS-based score, the Dynamic Ultrasound Congestion Score (DUCS), was developed. DUCS integrates lung ultrasound and Venous Excess Ultrasound (VExUS) to dynamically evaluate congestion severity, treatment response, and therapeutic goals during ADHF management. Observational data suggest that DUCS is associated with in-hospital outcomes and short-term prognosis, and correlates with markers of decongestion such as urinary output and weight loss. This study is a randomized, single-center, single-blind clinical trial designed to evaluate whether a DUCS-guided POCUS strategy improves clinical and decongestion outcomes compared with standard of care. Eligible patients hospitalized due to ADHF will be randomized within 48 hours of admission to one of two groups: (1) diuretic treatment guided by institutional standard-of-care combined with information from the EVEREST congestion score assessment and guideline-based treatment recommendations; or (2) diuretic treatment guided by serial DUCS-based POCUS assessments used to inform diuretic adjustment recommendations. Participants in both groups will undergo evaluations at baseline (day 1), day 2, day 3 and day 5, including clinical data collection, physical examination using the EVEREST congestion score, and standardized DUCS-based POCUS assessments. Outcomes to be assessed include in-hospital mortality, length of hospital stay, decongestion parameters, and changes in biomarkers.

Start Date23 Mar 2026

Sponsor / Collaborator

Hospital de Clínicas de Porto Alegre HCPA

100 Clinical Results associated with Hydrochlorothiazide

100 Translational Medicine associated with Hydrochlorothiazide

100 Patents (Medical) associated with Hydrochlorothiazide

10,853

Literatures (Medical) associated with Hydrochlorothiazide

31 Dec 2026·BLOOD PRESSURE

24-month single-pill, triple antihypertensive therapy in rural Rwanda

Article

Author: Parati, Gianfranco ; Umulisa, Alice ; Muvunyi, Bienvenu ; Bianchetti, Mario G. ; Lava, Sebastiano A. G. ; Hunjan, Isabella ; Ntaganda, Evariste ; Stroppa, Clara ; Mucyo, Willy ; Muggli, Franco

INTRODUCTION:

Arterial hypertension is a leading modifiable cardiovascular risk factor. Recent guidelines recommend single-pill, low-dose combinations as initial pharmacological strategy. We investigated the long-term feasibility and sustained effect of such a strategy in a remote rural area of Southern Rwanda, in sub-Saharan Africa.

METHODS:

Hypertension was diagnosed using three sets of blood pressure measurements obtained according to European Society of Hypertension recommendations using a validated oscillometric device (OMRON M7 IT-HEM-7322-E). Individuals meeting diagnostic criteria were initiated on a single-pill combination of amlodipine, hydrochlorothiazide, and olmesartan. Treatment dosage was reassessed and adjusted as needed at each outpatient clinic visit.

RESULTS:

Fifty-seven Black African participants with confirmed uncomplicated, untreated hypertension (aged 65 [54-70] years; median and interquartile range) had follow-up data available for up to 24 months after inclusion. Blood pressure <140/90 mm Hg was achieved in 37 (65%) participants after 1 month, 51 (89%) after 3 months, 44 (77%) after 6 months, 43 (75%) after 12 months, and 47 (83%) after 24 months.

CONCLUSION:

Long-term management of arterial hypertension with a once-daily single-pill combination of amlodipine, hydrochlorothiazide, and olmesartan as initial therapy is feasible in a rural sub-Saharan African setting. Blood pressure reduction is sustained for at least 24 months. Single-pill combinations should be made accessible even in remote areas of low- and middle-income countries.

01 Oct 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Determination of five antihypertensives in dried capillary plasma spots by LC-MS/MS: A novel method for monitoring pharmacotherapy adherence

Article

Author: Augustin, Carla Miriane ; Charão, Mariele Feiffer ; Duarte, Juliana Henrique ; Antunes, Marina Venzon ; Linden, Rafael ; Fischer Costa, Fernanda ; Betti, Andresa Heemann ; Roieski, Eduarda ; Oliveira, Debora Renata Macali

Adherence to hypertension treatment is crucial for therapeutic success, as noncompliance adversely affects quality of life and healthcare costs. Assessing adherence directly through plasma drug concentrations is particularly effective for patients with complex medication regimens. This study aimed to develop and validate an LC-MS/MS method for quantifying five antihypertensive drugs in dried capillary plasma obtained via a plasma separation device. The process involved incubating three 6 mm discs in 150 µL of 0.1% bovine serum albumin, followed by chloride analysis of a 20 µL aliquot after 45 min. The residual volume was precipitated using 25% trichloroacetic acid, then mixed with 500 µL methanol containing internal standards (losartan-D4 and atenolol-D7). The extract was dried, reconstituted with methanol, and combined with the supernatant from protein precipitation for analysis. An octadecylsilic column and gradient elution with 0.1% formic acid in water and acetonitrile were used, with positive electrospray ionization except for hydrochlorothiazide. The analytical run time was eight minutes, exhibiting linear ranges from 0.5 to 200 ng/mL for amlodipine and losartan and 5-2000 ng/mL for atenolol, hydrochlorothiazide, and losartan, with r² > 0.99 and 1/x weighting. Precision and accuracy were acceptable, with CV% ranging from 4.3% to 14.5% and accuracy from 86% to 112%, while extraction yields were between 75% and 101%. The analytes were stable at 23 ºC for 21 days in DPS samples. Comparison of drug concentrations in DPS and fresh plasma samples from 72 patients demonstrated high correlation (r = 0.93-0.98), indicating reliability in assessing therapy adherence. Lower concentrations of amlodipine, hydrochlorothiazide, and losartan were observed in patients exhibiting poor adherence (n = 21) compared to adherent patients (n = 51) with statistical significance (p < 0.05). The method is promising for assessing antihypertensive adherence using dried plasma spots.

01 Aug 2026·ENVIRONMENTAL RESEARCH

Pharmaceuticals, personal care-products and current-use pesticides: a review of the available data from European seas

Review

Author: León, Víctor M ; Munschy, Catherine ; Castro-Jiménez, Javier ; Aminot, Yann ; Mason, Claire ; Mil-Homens, Mário ; García-Pimentel, María Del Mar

Pharmaceuticals and personal care products (PPCPs) as well as current-use pesticides (CUPs) are considered to be contaminants of emerging concern (CECs), but there is limited information that exists about their occurrence and impact in the marine environment. A database of these CECs has been created as an overview of their occurrence and distribution in European marine waters by the ICES Marine Chemistry Working Group (MCWG) and collaborators from various European countries. The majority of the compiled data corresponded to pharmaceuticals in seawaters, but much less data were available for other matrices (biota and sediment) and CEC groups. Generally, concentrations were characterized for a limited spatial area and/or a small number of species/organisms. A Total Occurrence Index (TOI) was developed, taking into account the number of data available, the maximum concentrations and the frequency of detection together as indicators. The TOI provided estimates for the CECs in the database and has been used to identify the most relevant PPCPs and CUPs. The highest TOIs were found for the pharmaceuticals salicylic acid, hydrochlorothiazide, gemfibrozil, mefenamic acid, paracetamol and diclofenac; the PCPs 2-ethylhexyl-4-methoxycinnamate, 4-methylbenzylidene camphor, octocrylene, galaxolide, benzophenone-3 and tonalide; and the CUPs chlorpyrifos, chlorthal-dimethyl, simazine and irgarol. It is noted that additional data are required, particularly in the sediment and the biota matrices, to more fully understand the distribution and impact of these CECs in the marine environment, when considering the wide geographical distribution areas covered in this review. Further assessment is also required, to prioritise those CECs, based on which of them are expected to cause the most adverse toxic effects to marine ecosystems.

News (Medical) associated with Hydrochlorothiazide

01 Apr 2026

·www.prnewswire.com

Accord Healthcare US Reintroduces Hydrochlorothiazide Tablets, Expanding Access Across All Three Strengths

RALEIGH, N.C., April 1, 2026 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, committed to improving access to affordable medicines, today announced the re‑launch of Hydrochlorothiazide Tablets, USP in 12.5 mg, 25 mg, and 50 mg strengths. Hydrochlorothiazide tablets are approved as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy, along with edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Additionally, the product is approved for the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. "The return of Hydrochlorothiazide Tablets reflects Accord Healthcare's commitment to providing dependable access to essential medications across core therapeutic categories," said Nuvan Dassanaike, Senior Vice President, Digital & Marketing Operations. "This relaunch supports healthcare providers and patients who rely on established treatment options for managing hypertension and edema related conditions." Important Safety Information You should not take Hydrochlorothiazide Tablets if you have anuria or if you are hypersensitive to hydrochlorothiazide or other sulfonamide derived drugs. Hydrochlorothiazide can cause serious side effects including: Acute transient myopia and acute angle closure glaucoma. Symptoms may include sudden vision changes or eye pain and can occur within hours to weeks of starting the medication. Discontinue hydrochlorothiazide as quickly as possible if these occur. Severe fluid and electrolyte imbalance. This includes low sodium, low potassium, low chloride, or other mineral disturbances, which may present with weakness, confusion, dizziness, muscle cramps, or nausea. Worsening of kidney or liver problems. Thiazide diuretics may precipitate azotemia in severe renal disease, and even small shifts in electrolytes may trigger hepatic coma in patients with liver disease. May add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. Severe hypersensitivity reactions. These may include anaphylaxis, vasculitis, respiratory distress, and photosensitivity. Worsening of systemic lupus erythematosus, which has been reported with thiazide use. The most common side effects of Hydrochlorothiazide include hypotension; dizziness; weakness; gastrointestinal symptoms such as nausea, vomiting, or diarrhea; electrolyte disturbances; headache; photosensitivity; blurred vision; hyperuricemia; and signs of fluid imbalance. Additional reactions reported include pancreatitis, muscle spasms, rash, and elevated blood sugar. These are not all the possible side effects of Hydrochlorothiazide. For more information, ask your doctor or pharmacist. Hydrochlorothiazide should be used with caution during pregnancy. Routine use during normal pregnancy is inappropriate, and thiazides cross the placenta and may cause fetal or neonatal jaundice, thrombocytopenia, or other adverse reactions. Hydrochlorothiazide is also excreted in breast milk, and you should talk to your healthcare provider about whether to discontinue nursing or discontinue the medication. Further information about safety and potential side effects can be found in our Prescribing Information. For more information, please visit the Products page at Accord Healthcare US. About Accord Healthcare US Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord Healthcare is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord Healthcare is headquartered in Raleigh, North Carolina. The Intas network markets its products in 85 countries. To learn more, visit the Accord Healthcare website. References: Hydrochlorothiazide Tablets. Prescribing Information. Accord Healthcare. Media Contact: Lauren Wheeler Email: [email protected] SOURCE Accord Healthcare US 21% more press release views with Request a Demo

Drug Approval

05 Jan 2026

·www.biospace.com

Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension

Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive therapy – the first systemic hypertension treatment to target a new pathway in over 30 years. Allschwil, Switzerland – January 5, 2026 Idorsia Ltd (SIX: IDIA) announces that Health Canada has granted marketing authorization for JERAYGO ™ (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products. 1 The recommended dose is 12.5 mg orally once daily. The dose can be increased to 25 mg once daily for patients tolerating the 12.5 mg dose and in need of tighter blood pressure (BP) control. 1 Hypertension remains a leading global health challenge and the number one modifiable risk factor for early morbidity and mortality. Despite advances in treatment, many patients still struggle with uncontrolled blood pressure, leaving them at significantly higher risk of heart attack, stroke, kidney failure, and premature death. Approximately 10% of hypertensive patients have resistant hypertension 3 , 4 – defined by uncontrolled blood pressure despite receiving at least three antihypertensive medications from different classes, at optimal doses – underscoring the urgent need for more effective therapies. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “JERAYGO is the first and only hypertension treatment to target the endothelin pathway, a fundamental yet previously unaddressed driver of disease onset, progression, and complications. The results of PRECISION show that targeting the endothelin pathway is crucial to adequately manage uncontrolled blood pressure. JERAYGO has demonstrated rapid, durable, and clinically significant double-digit blood pressure reduction across a broad spectrum of challenging patient populations, including those with obesity, chronic kidney disease, or type 2 diabetes. I am very proud of our team for achieving this milestone.” Idorsia is engaged in discussions to maximize the ability to make JERAYGO available to patients. For more information on the marketing authorization of JERAYGO in Canada and important safety information, please review the Product Monograph . Notes to the editor About the Phase 3 PRECISION study 1,5 The efficacy of aprocitentan was evaluated in one randomized, double-blind (DB), placebo-controlled Phase 3 multicenter study. Patients with uncontrolled blood pressure (systolic blood pressure [SBP] ≥140 mmHg) despite the use of at least three antihypertensive medicinal products and following exclusion of pseudo-resistant hypertension (e.g., white coat effect, inappropriate blood pressure measurement, secondary causes of hypertension) were considered to have resistant hypertension. The patients were switched to standardized background antihypertensive therapy consisting of an angiotensin receptor blocker (valsartan 160 mg), a calcium channel blocker (amlodipine 5 or 10 mg), and a diuretic (hydrochlorothiazide 25 mg) throughout the study. Patients with concomitant use of beta-blockers continued this treatment throughout the study, in addition to the standardized background antihypertensive therapy and study treatment. A total of 730 patients received either aprocitentan 12.5 mg, aprocitentan 25 mg, or placebo once daily during the initial 4-week DB treatment (part 1). Thereafter, patients received aprocitentan 25 mg once daily during the 32-week single-blind treatment (part 2). At the end of the 32 weeks, patients were re-randomized to receive either aprocitentan 25 mg or placebo, once daily, during the 12-week double-blind withdrawal (DB-WD) treatment (part 3). The primary efficacy endpoint was the change in sitting SBP (SiSBP) from baseline to Week 4 during DB treatment (part 1), measured at trough by unattended automated office blood pressure (uAOBP). The key secondary endpoint was the change in SiSBP measured at trough by uAOBP from DB-WD baseline (Week 36) to Week 40 (part 3). Patients had a mean age of 61.7 years (range 24 to 84 years; 34.1% were ≥ 65 and < 75 years; 9.9% were ≥ 75 years) and 59.5% were male. Patients were White (82.9%), African American (11.2%) or Asian (5.2%). The mean body weight was 97.6 kg (range 46 to 196 kg) and mean BMI was 33.7 kg/m2 (range 18 to 64 kg/m2). Patients had a medical history of type 2 diabetes mellitus (54.1%), ischemic heart disease (30.8%), central nervous system vascular disorders (23.0%), chronic kidney disease stages 3 and 4 (22.2%; 19.3% of patients had eGFR 30–59 mL/min/1.73 m2 and 2.9% had eGFR 15–29 mL/min/1.73 m2), congestive heart failure (19.6%), and sleep apnea syndrome (14.1%). 63.0% of patients had four or more antihypertensive medicinal products. Key PRECISION findings 1,5 Doses of aprocitentan 12.5 and 25 mg showed a statistically significant reduction vs placebo on SiSBP at Week 4. The treatment effect was consistent for sitting diastolic blood pressure (SiDBP). The persistence of the BP-lowering effect of aprocitentan was shown in DB-WD treatment (part 3). In patients re-randomized to placebo, the mean SiSBP increased, whereas in patients re-randomized to aprocitentan 25 mg the mean effect on SiSBP was stable, resulting in a statistically significant difference. The treatment effect was consistent for SiDBP. The effect was also consistent across SBP and DBP measured by ambulatory BP monitoring (ABPM) and assessed as daytime, night-time, and 24h periods at Week 4 and Week 40. A substantial proportion (i.e., at least 90%) of the BP-lowering effect was observed within the first two weeks of treatment with aprocitentan. The effect of aprocitentan was consistent across subgroups of age (including patients ≥ 75 years), sex, race (including patients with Black or African American origin), BMI, baseline urine albumin-to-creatinine ratio (UACR), baseline eGFR and medical history of diabetes. The most frequently reported adverse reactions with aprocitentan were edema/fluid retention (mostly peripheral edema) (9.1%, 12.5 mg; 18.4%, 25 mg) and hemoglobin decreased (3.7%, 12.5 mg; 1.2%, 25 mg). JERAYGO is contraindicated for use in women who are pregnant, breast-feeding, in women of childbearing potential who are not using reliable contraception, patients with severe hepatic impairment, and in patients with hypersensitivity to the active substance or to any of the excipients. About aprocitentan Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ET A and ET B receptors. Aprocitentan is approved as TRYVIO™ in the US for the treatment of systemic hypertension in combination with other antihypertensives and has been commercially available since October 2024. Aprocitentan is approved as JERAYGO™ for the treatment of resistant hypertension in combination with at least three antihypertensives in the European Union, the UK, and Switzerland, and now in Canada. Idorsia Pharmaceuticals Ltd has transferred its rights for aprocitentan (including JERAYGO™) to Idorsia Investments SARL to allow the repayment of notes issued in connection with the repurchase offer completed in August 2025. More details on the transfer can be found in the press release issued on May 21, 2025 and on the exchange offer in the press release issued on August 27, 2025. References JERAYGO ™ Product Monograph NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398:957-80. Noubiap JJ, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3·2 million patients. Heart 2019; 105: 98–105. Williams B, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021–104. Schlaich MP, et al. A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension. The Lancet, 2022; Dec 3;400(10367):1927-1937. About Idorsia The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact: Investor & Media Relations Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41 58 844 10 10 investor.relations@idorsia.com – media.relations@idorsia.com – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF

Clinical ResultDrug ApprovalPhase 3

09 Dec 2025

·www.drugs.com

Some Blood Pressure Pill Formulations of Bisoprolol and Hydrochlorothiazide, Recalled for Possible Contamination

TUESDAY, Dec. 9, 2025 — A widely used blood pressure medication is being pulled from shelves after testing suggested some batches may contain traces of other drugs. Glenmark Pharmaceuticals has recalled several lots of bisoprolol fumarate and hydrochlorothiazide tablets (sold under the brand name Ziac ), according to a notice posted by the U.S. Food and Drug Administration (FDA). The tablets may have been contaminated with ezetimibe , a cholesterol-lowering medicine the company also manufactures. The recall affects the following lots, as reported by USA Today : 30-tablet bottles, NDC-68462-878-30. Lot 17232401, exp. 11/2025. 30-tablet bottles, NDC-68462-878-30. Lot 17232401, exp. 11/2025. 100-tablet bottles, NDC-68462-878-01. Lot 17232401, exp. 11/2025. 100-tablet bottles, NDC-68462-878-01. Lot 17232401, exp. 11/2025. 500-tablet bottles, NDC-68462-878-05. Lots 17232401, exp. 11/2025 and 17240974, exp. 05/2026. 500-tablet bottles, NDC-68462-878-05. Lots 17232401, exp. 11/2025 and 17240974, exp. 05/2026. Samples tested at the manufacturer’s facility in Madhya Pradesh, India, showed the traces of ezetimibe. Regulators classified the recall as Class III, meaning the issue is not expected to cause serious health risks. But patients who think they may have medication from the recalled lots should check the packaging and contact their pharmacy or prescriber. Bisoprolol/hydrochlorothiazide is prescribed to treat high blood pressure by helping the heart beat more normally and removing extra water and sodium from the body. Lowering blood pressure can help reduce the risk of a heart attack and stroke . Neither Glenmark nor the FDA has issued specific instructions for patients yet, USA Today reported. Folks who have affected lot numbers should contact their health care provider and, if so instructed, safely dispose of the recalled medication. Sources USA Today, Dec. 6, 2025

100 Deals associated with Hydrochlorothiazide

External Link

KEGG	Wiki	ATC	Drug Bank
D00340	Hydrochlorothiazide	C03AA03	DB00999

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nephrotic Syndrome	United States	Novitium Pharma LLC	28 Jan 2025
Diabetes Insipidus	China	Grand Pharmaceutical Group	01 Jan 1981
Edema	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Nephrolithiasis	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Hypertension	United States	Novartis Pharmaceuticals Corp.	12 Feb 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 3	-	Boehringer Ingelheim GmbH	01 Jun 1998
Diabetes Mellitus, Type 2	Phase 2	Canada	Novartis Pharmaceuticals Canada, Inc.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03298802 (CTgov)	Phase 3	Pre-Eclampsia	453	Hydrochlorothiazide 50mg Tablet (Hydrochlorothiazide 50mg Tablet)	qznfsqqyqz = lopgpdftnk zxpnskcgww (lymztdxzsa, fzbbpccmre - qyzktczujg) View more	-	24 Jun 2026
				Placebo Tablet (Placebo Tablet)	qznfsqqyqz = arycohwenz zxpnskcgww (lymztdxzsa, bnoarjjdvw - dunrgdvsrb) View more
NCT02373163 (INTERVENCION Trial \| INTERVENCION, CTgov)	Phase 4	Hypertension	166	Hydrochlorothiazide (Diuretic)	spvlfvcbat(vhwjbahmtd) = bhqozbqimx jexfvqyoox (ovajrcexmv, 8.4) View more	-	29 Jul 2025
				Amlodipine (Calcium-channel Blocker)	spvlfvcbat(vhwjbahmtd) = tckyeaqbcd jexfvqyoox (ovajrcexmv, 9.2) View more
NCT03295734 (ACES, CTgov)	Phase 2	Hypertension	223	Aerobic exercise+Perindopril (Perindopril)	yndlknqbyt(slvrzsehsw) = hkkaqorgft giigoopfms (rokgsedfxi, izljjiywwk - nttiqasqoj) View more	-	22 Jul 2025
				Aerobic exercise+Losartan (Losartan)	yndlknqbyt(slvrzsehsw) = oqghqsymvy giigoopfms (rokgsedfxi, emaaegwlha - neyoezyxyg) View more
ESH2025	Not Applicable	Hypertension	1,606	Chlorthalidone	xdcpatmpev(paffboalzp) = kzowzelcrn hwxkwuohpa (epmkzcloiq ) View more	Positive	23 May 2025
				Hydrochlorothiazide	xdcpatmpev(paffboalzp) = yrnwihtizl hwxkwuohpa (epmkzcloiq ) View more
NCT00690521 (CTgov)	Not Applicable	Heart Failure \| Chronic congestive heart failure	8	Arm1+Hydrochlorothiazide+Metolazone+Furosemide (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone)	qdtkchgsqj = hvloyuvgbs mcobnhwsdh (rskmvotzgt, dvbmwszyxb - dnrpkaznql) View more	-	10 Oct 2024
				Arm2+Hydrochlorothiazide+Metolazone+Furosemide (Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide)	qdtkchgsqj = aakgaurvhm mcobnhwsdh (rskmvotzgt, yyjxgjnpcv - lpjpjryxuf) View more
NCT02185417 (DCP \| Diuretic Comparison Project \| Diuretic Comparison Project (DCP), CTgov)	Phase 3	Hypertension	20,723	Hydrochlorothiazide (HCTZ) (Hydrochlorothiazide)	qsvkkqucfe(bucyhgroav) = vnfqmlyjsh nmuhgfwdbr (yscmprusqz, 1.0) View more	-	22 May 2024
				Chlorthalidone (Chlorthalidone)	qsvkkqucfe(bucyhgroav) = yzghwxosbg nmuhgfwdbr (yscmprusqz, 1.0) View more
NCT02185417 (Diuretic Comparison Project (DCP), Pubmed \| JAMA Netw Open) Manual	Phase 3	Hypertension	13,523	Chlorthalidone (with prior MI or stroke at baseline)	gzaeqihund(nstoiymxud) = cskrewxdjv dnsmvwttyc (anvdkegkgj ) View more	Positive	01 May 2024
				Hydrochlorothiazide (with prior MI or stroke at baseline)	gzaeqihund(nstoiymxud) = vtlpydqwlj dnsmvwttyc (anvdkegkgj ) View more
NCT03057431 (NOSTONE, CTgov)	Phase 3	Kidney Calculi	416	Placebo oral capsule (Placebo)	pzjwegeyye = jkbjrmxzas rdejsrovnn (qxoowotkng, tqwfbuvvct - icmbcqaqed) View more	-	01 Feb 2024
				12.5 mg hydrochlorothiazide (12.5 mg Hydrochlorothiazide)	pzjwegeyye = qtbfzlbwmu rdejsrovnn (qxoowotkng, yflgquirjw - uruecglyjh) View more
NCT01647932 (CLOROTIC, Pubmed \| Rev Clin Esp (Barc)) Manual	Phase 3	Acute decompensated heart failure	230	Placebo	axjzrrpjzk(txjaberlkd) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex rwvmnxqdag (xayfnnkygk ) View more	Positive	11 Jan 2024
				furosemide+hydrochlorothiazide
EUCTR2013-001852-36-ES \| NCT01647932 (CLOROTIC, Pubmed \| Eur J Heart Fail)	Not Applicable	Heart Failure	230	HCTZ + furosemide	ddccinymlg(nudgjobkdl) = xikctxagld xwttnhysmw (lyukjvvabr )	-	04 Aug 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis